OXNARD, Calif., Jan. 03, 2018 -- CURE Pharmaceutical (OTCQB:CURR), (“CURE”), an innovative drug delivery and development company, will be a presenting company at the 2018 Biotech Showcase in San Francisco, CA, taking place January 8 -10, 2018.
“We look forward to sharing how CURE can improve the delivery of pharmaceuticals to improve patient outcomes and save money,” said Robert Davidson, CEO of CURE Pharmaceutical. “This has been a pivotal year. In addition to proving our technology’s effectiveness for pharmaceuticals, we’ve also expanded our patent portfolio, forged new partnerships with cutting-edge companies looking for new methods to deliver their proprietary molecules and attracted industry veterans to join our management team and board.
CURE will be presenting on January 10th at 9:30am. If you are interested in scheduling a meeting at the conference with CURE executives, please contact Euvy Tatunay at [email protected].
This event is considered a critical strategic benchmark for business development activities and is one of the year’s most important investor conferences. Biotech Showcase attracts a wide range of business leaders from large and midsize pharmaceutical companies, investors and other industry experts.
About CURE Pharmaceutical
CURE Pharmaceutical is a fully integrated life science company committed to improving drug efficacy, safety and the patient experience through its proprietary drug dosage forms and delivery systems. CURE has an industry leading full-service cGMP manufacturing facility and is a preeminent developer and manufacturer of a patented and proprietary delivery system (CureFilm™), the most advanced oral thin film on the market today. CURE has developed an array of products in cutting-edge delivery platforms and partners with leading pharmaceutical companies. CURE has positioned itself to advance numerous therapeutic categories, including the pharmaceutical cannabis sector with partnerships in the U.S., Canada, Israel and Germany, among other markets. The Company’s mission is to improve people’s lives by redefining how medicines are delivered and experienced.
For more information about CURE Pharmaceutical, please visit its website at www.curepharmaceutical.com.
Forward-looking statements
This press release contains forward-looking statements, which are subject to risks and uncertainties. All statements, other than statements of fact, including those statements with respect to the Company's business development, are forward-looking statements. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements.
Public Relations Contact
Andrew Hard
Chief Executive Officer
CMW Media
[email protected]
P. +1888 829-0070
www.cmwmedia.com


U.S. Judge Allows Jeffrey Epstein Sex Trafficking Lawsuit Against Bank of America to Proceed
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute
Novocure Stock Surges 30% After FDA Approves Optune Pax for Pancreatic Cancer Treatment
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks
Vale Reports $3.8 Billion Q4 Net Loss Amid Nickel Asset Impairment and Samarco Provisions
Westpac (ASX: WBC) Q1 Profit Rises 6% as Lending Growth and Treasury Income Strengthen Earnings
Converse Cuts Corporate Jobs as Nike Restructures to Revive Sales Growth
Instagram CEO Defends Platform in Youth Mental Health Lawsuit Over Social Media Addiction Claims
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act 



